Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-09-06

FDA Approved: PULMICORT FLEXHALER — Supplemental Application (H2-Pharma LLC)

View source ↗

Summary

The FDA approved a supplemental application for Pulmicort Flexhaler (budesonide) submitted by H2-Pharma LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • PULMICORT FLEXHALER (BUDESONIDE)

Snippet

SUPPL AP for PULMICORT FLEXHALER (BUDESONIDE)